DE60306904D1 - Selektive dipeptidische inhibitoren von kallikrein - Google Patents

Selektive dipeptidische inhibitoren von kallikrein

Info

Publication number
DE60306904D1
DE60306904D1 DE60306904T DE60306904T DE60306904D1 DE 60306904 D1 DE60306904 D1 DE 60306904D1 DE 60306904 T DE60306904 T DE 60306904T DE 60306904 T DE60306904 T DE 60306904T DE 60306904 D1 DE60306904 D1 DE 60306904D1
Authority
DE
Germany
Prior art keywords
callicle
dipeptidic
inhibitors
selective
selective dipeptidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60306904T
Other languages
English (en)
Other versions
DE60306904T2 (de
Inventor
David Michael Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vantia Ltd
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of DE60306904D1 publication Critical patent/DE60306904D1/de
Application granted granted Critical
Publication of DE60306904T2 publication Critical patent/DE60306904T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60306904T 2002-03-08 2003-03-04 Selektive dipeptidische inhibitoren von kallikrein Expired - Lifetime DE60306904T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0205527 2002-03-08
GBGB0205527.5A GB0205527D0 (en) 2002-03-08 2002-03-08 Inhibitors
PCT/GB2003/000908 WO2003076458A2 (en) 2002-03-08 2003-03-04 Selective dipeptide inhibitors of kallikrein

Publications (2)

Publication Number Publication Date
DE60306904D1 true DE60306904D1 (de) 2006-08-31
DE60306904T2 DE60306904T2 (de) 2007-02-08

Family

ID=9932619

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60306904T Expired - Lifetime DE60306904T2 (de) 2002-03-08 2003-03-04 Selektive dipeptidische inhibitoren von kallikrein

Country Status (27)

Country Link
US (1) US7649000B2 (de)
EP (1) EP1483284B1 (de)
JP (1) JP4330450B2 (de)
KR (1) KR100974633B1 (de)
CN (1) CN1274713C (de)
AR (1) AR039868A1 (de)
AT (1) ATE333463T1 (de)
AU (1) AU2003208471B2 (de)
CA (1) CA2478099C (de)
DE (1) DE60306904T2 (de)
DK (1) DK1483284T3 (de)
EG (1) EG25482A (de)
ES (1) ES2264523T3 (de)
GB (1) GB0205527D0 (de)
HK (1) HK1072265A1 (de)
IL (2) IL163710A0 (de)
MX (1) MXPA04008523A (de)
MY (1) MY130830A (de)
NO (1) NO332678B1 (de)
NZ (1) NZ534891A (de)
PL (1) PL209670B1 (de)
PT (1) PT1483284E (de)
RU (1) RU2301225C2 (de)
TW (1) TWI283685B (de)
UY (1) UY27699A1 (de)
WO (1) WO2003076458A2 (de)
ZA (1) ZA200406856B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736465A4 (de) 2004-03-31 2009-06-17 Ajinomoto Kk Anilinderivative
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
GB0918924D0 (en) * 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (de) 2012-01-27 2014-12-03 Novartis AG Aminopyridinderivate als plasma-kallikrein-inhibitoren
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PH12015501492B1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
WO2015022546A1 (en) 2013-08-14 2015-02-19 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
GB2517908A (en) * 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
JP2017502921A (ja) * 2013-10-28 2017-01-26 バイサイクル・セラピューティクス・リミテッド 新規なポリペプチド
JP6382997B2 (ja) 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
RU2020121151A (ru) 2017-11-29 2021-12-29 Калвиста Фармасьютикалз Лимитед Дозированные формы, содержащие ингибитор плазменного калликреина
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
US20230381162A1 (en) 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
WO1993008211A1 (en) * 1991-10-23 1993-04-29 The Procter & Gamble Company Tripeptide derivative anti-inflammatory agents
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
GB9318637D0 (en) 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors

Also Published As

Publication number Publication date
UY27699A1 (es) 2003-10-31
MY130830A (en) 2007-07-31
TW200403255A (en) 2004-03-01
JP2005533750A (ja) 2005-11-10
NO20043695L (no) 2004-10-07
AU2003208471A1 (en) 2003-09-22
ES2264523T3 (es) 2007-01-01
EP1483284A2 (de) 2004-12-08
CN1639186A (zh) 2005-07-13
NO332678B1 (no) 2012-12-03
DK1483284T3 (da) 2006-10-16
NZ534891A (en) 2006-03-31
EP1483284B1 (de) 2006-07-19
CN1274713C (zh) 2006-09-13
MXPA04008523A (es) 2004-12-06
TWI283685B (en) 2007-07-11
IL163710A0 (en) 2005-12-18
IL163710A (en) 2010-12-30
ATE333463T1 (de) 2006-08-15
RU2004126610A (ru) 2005-05-27
DE60306904T2 (de) 2007-02-08
RU2301225C2 (ru) 2007-06-20
WO2003076458A3 (en) 2003-11-06
US20060052313A1 (en) 2006-03-09
KR100974633B1 (ko) 2010-08-06
US7649000B2 (en) 2010-01-19
ZA200406856B (en) 2005-11-30
HK1072265A1 (en) 2005-08-19
KR20040089705A (ko) 2004-10-21
PL209670B1 (pl) 2011-10-31
AU2003208471B2 (en) 2006-09-28
PL372977A1 (en) 2005-08-08
GB0205527D0 (en) 2002-04-24
AR039868A1 (es) 2005-03-09
PT1483284E (pt) 2006-11-30
WO2003076458A2 (en) 2003-09-18
JP4330450B2 (ja) 2009-09-16
EG25482A (en) 2012-01-15
CA2478099A1 (en) 2003-09-18
CA2478099C (en) 2011-10-04

Similar Documents

Publication Publication Date Title
DE60306904D1 (de) Selektive dipeptidische inhibitoren von kallikrein
DE60320933D1 (de) Rho-kinase inhibitoren
DE60319430D1 (de) R- und fgfr-inhibitoren
DK1699455T3 (da) Heterocykliske aspartylproteasehæmmere
NO20034044L (no) Metallproteinase-inhibitorer
DE602005019971D1 (de) Inhibitoren von cysteinprotease
NO20034308D0 (no) Nye tyrokinase-inhibitorer
DK1505963T3 (da) Hepatitis C-inhibitorer
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
DE60234125D1 (de) E inhibitoren
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
EE200300439A (et) Metalloproteinaasi inhibiitorid
DE602004018837D1 (de) Ptidase-iv-inhibitoren
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
NO20034032L (no) Metallproteinase-inhibitorer
NO20050563L (no) N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
ATE373648T1 (de) Nf-kappab-inhibitoren
DK1453852T3 (da) Selektive arylguanidinpeptider som urokinaseinhibitorer
NO20043610L (no) Fenylpyrimidinaminer som IgE inhibitorer
DE60331820D1 (de) Beseitigung von verstopfungen von rohrleitungen
DE602004014762D1 (de) Proteasehemmer
DOP2001000307A (es) Inhibidores de thrombin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: VANTIA LTD., CHILWORTH, GB

R082 Change of representative

Ref document number: 1483284

Country of ref document: EP

Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAELTE,